Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?

American Surgeon

Volumn 78, Issue 9, 2012, Pages 992-999

  Arslan, Cagatay ^a,b   Isik, Metin ^b   Guler, Gulnur ^b   Kulac, Ibrahim ^b   Solak, Mustafa ^b   Turker, Burcu ^b   Ozisik, Yavuz ^b   Altundag, Kadri ^b  

^a Izmir Tepecik Training and Research Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; OVERALL SURVIVAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TUMOR VOLUME; VISCERAL METASTASIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84865974680     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Conzen SD, Grushko TA, Olopade OI. The molecular biology of breast cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg, SA, eds. Cancer: Principles&Practice of Oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:1597-650.
2. Kuene-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996;32:1560-5. (Pubitemid 26279124)
3. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:95-103. (Pubitemid 128513223)
4. Brys M. Androgens and androgen receptor: do they play a role in breast cancer? Med Sci Monit 2000;6:433-8. (Pubitemid 30313190)
5. Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002;20:175-89. (Pubitemid 34233739)
6. Langer M, Kubista E, Schemper M, Spona J. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet 1990;247:203-9. (Pubitemid 20232513)
7. Hall RE, Aspinall JO, Horsfall DJ, et al. Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer 1996;74: 1175-80. (Pubitemid 26360103)
8. Soreide JA, Lea OA, Kvinnsland S. Progesterone binding cyst protein (PBCP = GCDFP-24) and steroid hormone receptors as markers of differentiation in breast cancer. Inverse relation of distribution in normal and malignant tissue of the same breast. Anticancer Res 1991;11:132-6.
9. Hall RE, Clements JA, Birrel SN, Tilley WD. Prostate specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 1998;78: 360-5. (Pubitemid 28336423)
10. Hackenberg R, Schulz KD. Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen- and androgen like steroids. J Steroid Biochem Mol Biol 1996;56:113-7. (Pubitemid 26107886)
11. Honma N, Sakamoto G, Akiyama F, et al. Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status. Histopathology 2003;42:120-7. (Pubitemid 36237843)
12. Riva C, Dainese E, Caprara G, et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 2005; 447:695-700. (Pubitemid 41571184)
13. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82. (Pubitemid 36515283)
14. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-67.
15. Hackenberg R, Turgetto I, Filmer A, Schulz KD. Estrogen and androgen stimulation and inhibition of proliferation by androst- 5-ene-3 beta-diol in human mammary cancer cells. J Steroid Biochem Mol Biol 1993;46:597-603. (Pubitemid 23346143)
16. Doane AS, Danso M, Lal P, et al. An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008. (Pubitemid 43990755)
17. Perou C, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
18. Hu R, Dawood S, Holmes MD, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res 2011;17:1867-74.
19. Castellano I, Allia E, Accortanzo V, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010;124: 607-17.
20. Agrawal AK, Jeleń M, Grzebieniak Z, et al. Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol 2008;46:269-76.
21. Micello D, Marando A, Sahnane N, et al. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancer. Virchows Arch 2010;457:467-76.
22. Verma S, Lavasani S, Mackey J, et al. Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol 2010;17:20-33.
23. Horiguchi J, Oyama T, Takata D, et al. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a singleinstitute experience. Anticancer Res 2011;31:3041-6.
24. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365: 1273-83.
25. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15: 2472-8.
26. Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-31. (Pubitemid 37339680)
27. Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011;24: 924-31.
28. Birrell SN, Hall RE, Tilley WD. Role of the androgen receptor in human breast cancer. J Mammary Gland Biol Neoplasia 1998;3:95-103. (Pubitemid 128513223)
29. Park S, Koo J, Park HS, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21:488-92.
30. Hardin C, Pommier R, Calhoun K, et al. A new hormonal therapy for estrogen receptor-negative breast cancer. World J Surg 2007;31:1041-6. (Pubitemid 46716787)
31. Niemeier LA, Dabbs DJ, Beriwal S, et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010;23:205-12.
32. Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptornegative breast cancer. Neoplasia 2011;13:154-66.
33. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13: R36.
34. Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20: 119-31.
35. Kuene-Boumeester V, Van der Kwast TH, Claassen CC, et al. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996;32:1560-5. (Pubitemid 26279124)
36. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J Pathol 1993;170:31-5. (Pubitemid 23130581)
37. Narita D, Raica M, Suciu C, et al. Immunohistochemical expression of androgen receptor and prostate specific antigen in breast cancer. Folia Histochem Cytobiol 2006;44: 165-72. (Pubitemid 44131983)
38. He J, Peng R, Yuan Z, et al. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2012;29:406-10.
39. Loibl S, Müller BM, von Minckwitz G, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;130:477-87.
40. Tang D, Xu S, Zhang Q, Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 2012;29:526-33.
41. Luo X, Shi YX, Li ZM, Jiang WQ. Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer. 2010;29:585-90.